UNSPSC 51182071: Testosterone enanthate

This classification denotes a therapeutic testosterone with the molecular formula C26H40O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Z6522T8N9, chemically known as 17-hydroxyandrost-4-en-3-one, 17-heptanoate but more generally known as testosterone enantate, which bears US NIH Compound Identifier 9416. European Medicines Agency schedules Testosterone enantate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04736MIG.

Most nations, for tariff and trade purposes, schedule testosterone enanthate under HS 29372900 and SITC 54153. As of Q4 2014, TESTOSTERONE ENANTHATE remains US FDA's Preferred Term for this commodity. Testosterone enanthate bears US NLM identifiers UMLS ID C0076189 and NCI Concept Code C1247. SMILES: CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C.

UNSPSC 51182071 Testosterone enanthate is a Commodity code covering pharmaceutical active pharmaceutical ingredients and finished-dose medications, but the recent state and local solicitation activity under this code reflects broad multi-source generic pharmaceutical procurement rather than testosterone enanthate specifically. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicited manufacturers and distributors of generic multi-source pharmaceuticals and over-the-counter products under a cooperative purchasing vehicle designed to serve participating state and local government facilities across multiple states including Oregon. The scope encompasses submission of detailed product information including National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength, dosage form, and packaging configurations, with vendors required to maintain contractual relationships with authorized wholesalers and comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). Issuing bodies are typically state pharmacy procurement offices and cooperative purchasing consortiums serving state agencies and local health systems, though this code shows limited recent activity in the available opportunities block.

MMCAP's RFP closed March 26, 2026, with contract awards effective July 1, 2026 for a two-year term with optional extensions. Evaluation weighted price competitiveness at 75 percent, with the remaining 25 percent split across fixed pricing, administrative compliance, EDI capability, and willingness to accept a 3 percent administrative fee on all purchases. Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, and products must possess FDA compliance and expiration dates of at least one year from manufacture with a minimum six-month shelf life. The cooperative purchasing structure channels awards through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials. No specific set-aside designations were identified in the available documentation, and no award values or budget ranges were disclosed in solicitation materials.